US Bancorp
DNTH icon

US Bancorp’s Dianthus Therapeutics DNTH Stock Holding History

US Bancorp’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$462K Buy
4,738
+16
+0.3% +$1.4K ﹤0.01% 1626
2026
Q1 		$396K Buy
4,722
+3,454
+272% +$200K ﹤0.01% 1627
2025
Q4 		$52.3K Sell
1,268
-130
-9% -$5.04K ﹤0.01% 2680
2025
Q3 		$55K Sell
1,398
-43
-3% -$1.1K ﹤0.01% 2629
2025
Q2 		$26.8K Sell
1,441
-144
-9% -$2.7K ﹤0.01% 3060
2025
Q1 		$28.8K Buy
1,585
+1,510
+2,013% +$33.3K ﹤0.01% 3009
2024
Q4 		$1.64K Buy
75
+10
+15% +$257 ﹤0.01% 3892
2024
Q3 		$1.78K Buy
+65
New +$1.81K ﹤0.01% 3817

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

US Bancorp's DNTH Position: Q2 2026 in Review

US Bancorp increased its Dianthus Therapeutics (DNTH) stake by 0.34% in Q2 2026, buying an estimated $1.4K and bringing the position to 4,738 shares worth $462K. The position accounts for ﹤0.01% of the portfolio, ranked #1626.

US Bancorp first reported a position in DNTH in Q3 2024 and has held it in 8 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • US Bancorp held 4,738 shares of Dianthus Therapeutics worth $462K as of Q2 2026.
  • US Bancorp bought 16 Dianthus Therapeutics shares in Q2 2026, an estimated $1.4K.
  • Dianthus Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1626 holding.
  • US Bancorp first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.